ORGO NASDAQ
Organogenesis Holdings Inc.
1W: +2.7%
1M: +10.4%
3M: -33.3%
YTD: -42.7%
1Y: -18.4%
3Y: -12.5%
5Y: -85.8%
$2.66
+0.00 (+0.00%)
Weekly Expected Move ±10.4%
$2
$2
$2
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (37)
Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update
Organogenesis (ORGO) Q1 2026 Earnings Transcript
12 Health Care Stocks Moving In Friday's Pre-Market Session
Forward Air Posts Downbeat Q1 Results, Joins Upwork, HubSpot And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Forward Air Posts Downbeat Q1 Results, Joins Upwork, HubSpot And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Organogenesis forecasts $270M-$310M 2026 revenue amid prolonged CMS-related recovery
[10-Q] Organogenesis Holdings Inc. Quarterly Earnings Report - Stock Titan
Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
Here are the major earnings after the close Thursday
Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®
What's Going On With Organogenesis Stock On Wednesday?
Organogenesis Stock Rockets After Diabetic Foot Ulcer Trial Posts Statistically Significant Win
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Organogenesis rises as PuraPlyAM succeeds in diabetic foot ulcers
Why Silo Pharma Shares Are Trading Higher By Around 52%; Here Are 20 Stocks Moving Premarket
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
SG Americas Securities LLC Acquires 376,623 Shares of Organogenesis $ORGO
Assenagon Asset Management S.A. Acquires 680,392 Shares of Organogenesis $ORGO
Organogenesis projects 25%-38% revenue decline in 2026 amid CMS-driven market disruption
Organogenesis Holdings Inc. (ORGO) Q4 2025 Earnings Call Transcript
Organogenesis Holdings GAAP EPS of $0.24 beats by $0.03, revenue of $225.1M beats by $52.42M
Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Organogenesis (NASDAQ:ORGO) Trading Down 5% – Time to Sell?
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Organogenesis Announces Initiation of Biologics License Application for ReNu®
Assenagon Asset Management S.A. Has $20.49 Million Stock Position in Organogenesis $ORGO
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
Organogenesis: High-Tech Skin Substitute Company On Sale